March 14, 2025
| Today’s news and insights for biopharma leaders
The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting that's typically held was canceled last month.
|
News roundup
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.
|
UPDATED
No biotech has priced an IPO since Aardvark one month ago, although a few remain in the queue and others, like Bluejay Therapeutics, are reportedly considering putting an offering together.
|
Enhancing manufacturability is crucial for reducing the risks associated with scaling production.
|
From the archives
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.
|
|
It’s time for healthcare sales teams to rethink how they connect with customers. Learn why more sales teams are investing in training that teaches a human-centered approach to sales in this playbook.
|
|
From Our Library
Webinar - on demand
Custom content for Certara
|
Playbook
Custom content for Real Chemistry
|
Playbook
Custom content for Hy-Tek Intralogistics
|
View all resources
What We’re Reading
The Boston Globe
|
| 
